Keen Eye Launches Its Next-Gen Platform To Accelerate Clinical Trials With AI-powered Digital Pathology, Now Fully Enabling Compliance With Good Clinical & Laboratory Practices

It enables every actor in Pathology to run digital image analysis in the context of clinical trials, as in CAP/CLIA laboratories, with unprecedented efficiency. This AI-platform strengthens Keen Eye’s strategic positioning in the clinical research market subject to GCLP regulations.

Keen Eye, a French health tech company building Deep Learning technology solutions for research and clinical studies, announces the launch of their new platform. This AI (Artificial Intelligence) web-based platform is dedicated to organizations conducting clinical trial assays in an environment following GCLP (Good Clinical Laboratory Practices) principles.

Recommended AI News: Celerium Adds CMMC Level 3 Suppliers Course To Supply Chain Cybersecurity Education Program

By strengthening its portfolio of products and services, Keen Eye takes a true competitive advantage and reinforces its leadership in AI-based digital image analysis in Pathology. “It provides a quantum leap in performance while contributing to regulatory compliance, hence paving the way for better standards in clinical image analysis. We are proud to have developed the solution every pharma and CRO has been waiting for,” comments Sylvain Berlemont, CEO and founder of Keen Eye.

Keen Eye’s next-generation platform addresses the safety of clinical trial subjects along with the integrity of data. Quality controls are implemented throughout workflows and records are signed using electronic signatures. These features are completed by an audit trail that captures every action performed on the platform.

For Dr. Jacques Bosq, former head of pathology at Institut Gustave Roussy, France, “As pathologists, we always put patients’ interests first. Keen Eye’s expertise in digital tissue analysis has proven to be a really effective solution. With this innovative GCLP-compliant platform, pathologists will be able to perform biomarker detection and quantification in clinical study protocols in a reliable, standardised and efficient manner.”

Recommended AI News: Qualifio Appoints Quentin Paquot As New CEO